Main Article

Salt Lake City-based Myriad Genetics’s second quarter 2009 molecular diagnostic revenues climbed 58 percent to $84 million, driven primarily by the company’s strategy to penetrate the women’s health diagnostic testing market. Myriad recently expanded its ob/gyn salesforce to 100, bringing the company’s total salesforce to 250.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2009 - Table of Contents

LIR March 2009 (full PDF issue)

G-2 Predicts Mol Dx Testing to Grow 12% in 2009 to $5.6 Billion in Favorable Pricing Environment

Esoteric Business Drives LabCorp’s FY2008 Revenue Up 10% to $4.5 Billion, Q408 Revenue Up 11.3% to $1.1 Billion

Sonic’s Acquisition Strategy Drives Revenue Up 28% to $938M for First Half FY2009; U.S. Organic Revenue Up 6%

Bio-Reference Courier System Improvements Boosts Efficiency, Sees Seven Month ROI

Inside the Lab Industry: Mol Dx Labs and Manufacturers Confront Tight Capital Market

Aurora Diagnostics’s Revenue Up Over 100% to $150 Million in 2008

DTC Advertising, Sales Effort Expansion Drives Myriad’s Q2 Revenues Up 58% for Q209

Response Genetics Consolidates Operations by Shuttering U.K. Operation

Lab Stocks Experience Uptick in February; Up 10% Over 13 Weeks

Industry Buzz: Bostwick Laboratories Launches Hematopath Division, Names Medical Director